Medical Condition News

RSS

Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions

Stealth Peptides, a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with significant unmet medical needs, introduced its lead clinical candidate, Bendavia, a novel compound that targets the mitochondrion, at the 2010 American Heart Association's (AHA) Scientific Sessions, Resuscitation Science Symposium.

22 Nov 2010

New study links high prevalence of insomnia and poor quality of life in software engineers

Insomnia is bad news for software engineers' quality of life and deserves greater recognition and attention, according to new research by Sara Sarrafi Zadeh and Khyrunnisa Begum from the University of Mysore in India. Their work shows that poor sleep has a bearing on quality of life - affecting physical and mental health in particular - in this group with high levels of job-related stress. Their paper is published online in Springer's journal Applied Research in Quality of Life.

22 Nov 2010

ImmunGene awarded $244,479 therapeutic discovery project grant under PPACA 2010

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that it has received a $244,479 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA). The grant was related to the development of ImmunGene's technology which is based on antibody-cytokine fusions that have demonstrated targeted toxicity and added tumor benefits.

22 Nov 2010

Convergence enters drug discovery collaboration with Selcia for chronic pain treatment

Convergence Pharmaceuticals Limited, the new company focused on the development of novel and high value analgesic medicines, and Selcia Limited, a contract research organisation, today are pleased to announce that they have entered into a drug discovery collaboration to identify and develop high quality candidate molecules for the treatment of chronic pain.

22 Nov 2010

Epilepsy Foundation Northwest adds Alaska to territory

The Epilepsy Foundation Northwest (EFNW) announced the addition of Alaska to its affiliate, making it the largest territory in the nation for the Epilepsy Foundation organization. Programs and services provided by EFNW for people living with epilepsy and their families will now officially include Alaska.

22 Nov 2010

Cell Therapeutics announces preliminary results of phase II OPAXIO study for high-grade gliomas

Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.

22 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Research shows association between childhood CKD and maternal diabetes, obesity

Children with Chronic Kidney Disease (CKD) are more likely to have mothers who were obese or had diabetes during pregnancy, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition, by Christine W. Hsu, MD (University of Washington, Seattle) and colleagues.

22 Nov 2010

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.

22 Nov 2010

Study finds no link between prostate cancer clinical stage and risk of recurrence after radical prostatectomy

A new study challenges the current staging system that determines the extent or severity of prostate cancer that has not metastasized. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study found that there is no link between localized prostate cancer's clinical stage and a patient's risk of cancer recurrence after having his prostate removed.

22 Nov 2010

Researchers develop three-dimensional cancer cell from normal human tissue in culture dish

Researchers at the Stanford University School of Medicine have successfully transformed normal human tissue into three-dimensional cancers in a tissue culture dish for the first time. Watching how the cells behave as they divide and invade surrounding tissue will help physicians better understand how human cancers act in the body. The new technique also provides a way to quickly and cheaply test anti-cancer drugs without requiring laboratory animals.

22 Nov 2010

Study finds common gene variant in African Americans increases risk of kidney disease

In African Americans with kidney disease related to hypertension (high blood pressure), a common gene variant is associated with a sharply increased risk of progressive kidney disease, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition. End Stage Renal Disease (ESRD) associated with hypertension occurs in the African American population at a rate 13.1 times greater than that of their white counterparts.

22 Nov 2010

Research indicates possible danger of cancerous tissue development by using stem cells

Research work carried out at the Hebrew University of Jerusalem arouses a cautionary warning in the growing field of the development of stem cells as a means for future treatment of patients through replacement of diseased or damaged tissues by using the patient's own stem cells. The research indicates a possible danger of cancerous tissue development in the use of such cells.

22 Nov 2010

SHARP study shows cholesterol-lowering effective for patients with kidney disease

Around a quarter of all heart attacks, strokes, and operations to open blocked arteries could be avoided in people with chronic kidney disease by using the combination of ezetimibe and simvastatin to lower blood cholesterol levels. That's the conclusion from the world's largest ever randomized trial in kidney disease.

22 Nov 2010

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug.

22 Nov 2010

Researchers reconstitute first step of break repair in cancerous cells

What prompts normal cells to transform themselves into cancerous cells. Researchers from Texas institutions, including the UT Health Science Center San Antonio, have identified factors in the very first step of the process and reconstituted this first step in the test tube. The latter accomplishment was reported Sunday [Nov. 21] in the top-tier journal Nature Structural & Molecular Biology.

22 Nov 2010

Inexpensive intervention helps patients with hypertension-associated kidney disease

In patients with kidney disease, the Western diet produces an acidic environment in the body that has numerous negative effects and worsens with age as kidney function declines.

21 Nov 2010

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.

21 Nov 2010

Presence of albumin in urine predicts cognitive decline: Study

A new study has found that low amounts of albumin in the urine, at levels not traditionally considered clinically significant, strongly predict faster cognitive decline in older women.

21 Nov 2010

Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting

Celldex Therapeutics, Inc., today announced the presentation of complete data for the primary endpoint of ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed glioblastoma multiforme (GBM).

21 Nov 2010

Medical Condition News

Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions

New study links high prevalence of insomnia and poor quality of life in software engineers

ImmunGene awarded $244,479 therapeutic discovery project grant under PPACA 2010

Convergence enters drug discovery collaboration with Selcia for chronic pain treatment

Epilepsy Foundation Northwest adds Alaska to territory

Cell Therapeutics announces preliminary results of phase II OPAXIO study for high-grade gliomas

VYTORIN reduces major vascular events in patients with chronic kidney disease

Research shows association between childhood CKD and maternal diabetes, obesity

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Study finds no link between prostate cancer clinical stage and risk of recurrence after radical prostatectomy

Researchers develop three-dimensional cancer cell from normal human tissue in culture dish

Study finds common gene variant in African Americans increases risk of kidney disease

Research indicates possible danger of cancerous tissue development by using stem cells

SHARP study shows cholesterol-lowering effective for patients with kidney disease

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Researchers reconstitute first step of break repair in cancerous cells

Inexpensive intervention helps patients with hypertension-associated kidney disease

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Presence of albumin in urine predicts cognitive decline: Study

Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News